行情

LGND

LGND

Ligand Pharma
NASDAQ

实时行情|Nasdaq Last Sale

115.45
-1.01
-0.87%
已收盘, 16:26 08/06 EDT
开盘
115.44
昨收
116.46
最高
116.73
最低
113.91
成交量
15.05万
成交额
--
52周最高
127.80
52周最低
57.24
市值
18.53亿
市盈率(TTM)
-83.8356
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测LGND价格均价为184.00,最高价位229.00,最低价为145.00。

EPS

LGND 新闻

更多
基石药业-B(02616):抗PD-L1单抗CS1001-302研究在期中分析中达到了预设的主要研究终点
智通财经网 · 1天前
Ligand (LGND) Beats on Q2 Earnings & Sales, Raises View
Ligand (LGND) reports better-than-expected second-quarter 2020 earnings and revenues. Stock up.
Zacks · 2天前
Ligand Trounces Q2 Estimates by Helping Companies Make COVID-19 Drug Remdesivir
Ligand Pharmaceuticals' (NASDAQ: LGND) big slide in March was only short-lived. Its shares have rebounded nicely over the last several months and came into this week up 12% year to date. The biotech announced its second-quarter results before the market opened
Motley Fool · 3天前
Ligand Pharmaceuticals Inc (LGND) Q2 2020 Earnings Call Transcript
LGND earnings call for the period ending June 30, 2020.
Motley Fool · 3天前
Ligand Pharmaceuticals shares are trading higher after the company raised its FY20 EPS and sales guidance above analyst estimates.
Benzinga · 3天前
Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Beat Estimates
Ligand (LGND) delivered earnings and revenue surprises of 53.85% and 46.78%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3天前
Ligand Pharmaceuticals Raises FY2020 Adj EPS Guidance from $3.65 to $4.10 vs $3.71 Est; Raises FY2020 Sales Guidance from $140.00M to $165.00M vs $142.45M Est
Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2020 Adj EPS guidance from $3.65 to $4.10 vs $3.71 analyst estimate. Raises FY2020 sales outlook from $140.00 million to $165.00 million vs $142.45 million estimate.
Benzinga · 4天前
Ligand Reports Second Quarter 2020 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginn
Business Wire · 4天前

所属板块

生物技术和医学研究
-0.96%
制药与医学研究
-0.46%

热门股票

代码
价格
涨跌幅

LGND 简况

Ligand Pharmaceuticals Incorporated是一家生物制药公司,专注于开发及收购帮助医药企业探索及开发药品的技术。该公司运用的研究技术包括核受体分析、高通量计算机筛选、配方科学、肝脏靶向的前体药物技术以及抗体探究技术。这些技术用于支持与企业的处方药批准相关的工作。该公司与超过85家医药及生物技术公司合作并签署授权协议。该公司的140多项经批准计划正处于不同阶段的商业化及开发进程中。其合作伙伴针对癫痫、昏迷、癌症、糖尿病、心血管疾病、肌肉萎缩、肝病及肾病等领域开展临床开发计划。该公司正在研发用于治疗II型糖尿病的小分子胰高血糖素受体拮抗剂。
展开

微牛提供Ligand Pharmaceuticals Inc.(NASDAQ-LGND)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的LGND股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易LGND股票基本功能。